乳房假体周围恶性与良性积液的细胞因子比较分析
该研究评估了仅需50 µL抽吸液即可同时检测13种细胞因子的免疫学方法,比较8例恶性与9例良性乳房假体周围积液的细胞因子谱。结果显示IL-9、IL-10、IL-13、IL-22和/或干扰素γ浓度>1000 pg/mL可区分恶性与良性积液,而IL-6在良性积液中亦升高,无鉴别价值。细胞因子检测联合可溶性CD30水平可用于识别恶性积液,但需更大前瞻性队列验证。
要点
- 50 µL积液即可用流式细胞术同时检测13种细胞因子。
- IL-9、IL-10、IL-13、IL-22和/或IFN-γ>1000 pg/mL可鉴别恶性积液。
- IL-6在良恶性积液中均升高,不能用于鉴别。
核心结论
- 细胞因子检测联合可溶性CD30水平可用于识别乳房假体周围恶性积液。
- 恶性积液中独特的细胞因子表达模式有助于了解BIA-ALCL的发病机制和起源细胞。
- 研究结果需在更大前瞻性患者队列中验证。
研究设计与样本
- 在仅50 µL抽吸积液上进行免疫学检测,用流式细胞术同时测量13种细胞因子。
- 以BIA-ALCL和皮肤ALCL细胞系分泌的细胞因子作为临床研究基线。
- 比较8例恶性积液与9例良性积液的细胞因子浓度。
主要发现
- IL-9、IL-10、IL-13、IL-22和/或干扰素γ浓度>1000 pg/mL可区分恶性积液与良性积液。
- IL-6在良性积液中亦升高,不能区分良恶性积液。
- 已知IL-6是恶性细胞的驱动因子。
关键数值与推荐
- IL-9、IL-10、IL-13、IL-22和/或干扰素γ浓度>1000 pg/mL提示恶性积液。
- 细胞因子检测需结合可溶性CD30水平用于识别恶性积液。
临床怎么用
- 对乳房假体周围延迟性积液,可抽吸50 µL积液行细胞因子检测辅助鉴别良恶性。
- 细胞因子结果应结合可溶性CD30水平综合判断,避免不必要手术。
局限性
- 研究仅纳入8例恶性积液和9例良性积液,样本量小。
- 研究结果为初步发现,需更大前瞻性患者队列验证。
- 证据等级为Level of Evidence: 5。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More than 700 women have developed an anaplastic large T cell lymphoma (ALCL) surrounding textured surface breast implants, termed breast implant-associated ALCL (BIA-ALCL). Most patients with BIA-ALCL present with an accumulation of fluid (delayed seroma) around the implant. However, benign seromas without malignant cells complicating scar contracture, implant rupture, trauma, infection, and other causes are more common. For proper patient management and to avoid unnecessary surgery, a simple diagnostic test to identify malignant seromas is desirable. OBJECTIVES: The aim of this study was to develop an ancillary test for the diagnosis of malignant seromas and to gain insight into the nature of the malignant cells and their microenvironment. METHODS: We employed an immunologic assay on only 50 µL of aspirated seroma fluid. The assay measures 13 cytokines simultaneously by flow cytometry. To establish a baseline for clinical studies we measured cytokines secreted by BIA-ALCL and cutaneous ALCL lines. RESULTS: Our study of cell line culture supernatants, and 8 malignant compared with 9 benign seromas indicates that interleukin 9 (IL-9), IL-10, IL-13, IL-22, and/or interferon γ concentrations >1000 pg/mL distinguish malignant seromas from benign seromas. IL-6, known to be a driver of malignant cells, is also elevated in benign seromas and does not distinguish them from malignant seromas. CONCLUSIONS: The cytokine assay introduced in this study can be used together with levels of soluble CD30 to identify malignant seromas. Validation of these findings in a larger prospective patient cohort is warranted. The unique pattern of cytokine expression in malignant effusions surrounding breast implants gives further insight into the pathogenesis and cells of origin of BIA-ALCL. UNLABELLED: Level of Evidence: 5.
引用
- Kadin ME, Morgan J, Kouttab N, et al. Comparative Analysis of Cytokines of Tumor Cell Lines, Malignant and Benign Effusions Around Breast Implants. Aesthet Surg J. 2020. PMID: 31589747. doi:10.1093/asj/sjz243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。